Skip to main content

Articles

Leukemia, Oncology

Ponatinib, a Tyrosine Kinase Inhibitor, Active in Patients with Relapsed or Refractory Chronic Myeloid Leukemia and BCR-ABL T315I Mutation

Leukemia, Oncology

CPX-351 Improves Posttransplant Survival in Older Patients with High-Risk Acute Myeloid Leukemia

Leukemia, Oncology

Strategies to Reduce the Use of Tyrosine Kinase Inhibitors in CML

Practice Management

New Value Model Incorporates Long-Term Adverse Effects of Cancer Drugs

Multiple Myeloma, Oncology

HIV Drug Shows Promise in Refractory Multiple Myeloma

Multiple Myeloma, Oncology

Venetoclax plus Bortezomib and Dexamethasone Produces High Responses in Patients with Relapsed or Refractory Multiple Myeloma

Pacritinib Shows Good Efficacy in Myelofibrosis: Will the FDA Release Hold on the Drug?

Brentuximab Vedotin Improves Responses Lasting 4 Months in Cutaneous T-Cell Lymphoma

Leukemia, Oncology

Chemotherapy-Free Induction with Ibrutinib plus Rituximab Shows Unprecedented Efficacy in MCL

Pembrolizumab Produces Durable Responses in Relapsed or Refractory Cutaneous T-Cell Lymphoma

Page 96 of 244
Results 951 - 960 of 2434